IRESSA: The story so far

In 2009, IRESSA was approved as a treatment for 1st line advanced non-small cell lung cancer (NSCLC). This follows an interesting development journey from when it was first discovered 15 years ago through when it first became available for use in NSCLC in 2002 to today where it’s an approved advanced NSCLC treatment in 66 countries around the world. 

References

1. Woodburn JR et al. An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development. Proceedings of the American Association for Cancer Research Annual Meeting 1997; 38(0):633.
2. Kelly HC, et al. Phase I data of ZD1839 - an oral epidermal growth factor receptor tyrosine kinase inhibitor. Annals of Oncology 1998; 9(Suppl):109.
3. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21(12):2237-2246.
4. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290(16):2149-2158.
5. Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22(5):777-784.
6. Herbst, R.S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22(5):785-794.
7. Thatcher N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet; 366(9496):1527-1537.
8. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21):2129-2139.
9. Niho S et al. Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. Abstract presented at American Society of Clinical Oncology (ASCO) 2007 Annual Meeting, Chicago, USA, 1-5 June 2007; abs 7509. J Clin Oncol Suppl, 2007.
10. Douillard, J-Y. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). Data presented at WCLC, 2-6 September 2007.